Alpa Laboratories Ltd

NSE: ALPA · Pharmaceuticals · sector

₹48.36NSE close 2026-10-26

Key numbers

Market cap₹102 cr

Price₹48.36

52w high / low₹94 / ₹46

P/E28.8xSector median 27.9x

P/B0.6xSector median 2.9x

Book value₹88.5

Dividend yield–Sector median 0.48%

ROE2.5%Sector median 11.7%

ROCE3.3%Sector median 12.3%

OPM-1.0%Sector median 14.0%

Debt / equity0.01xSector median 0.16x

EV/EBITDA–Sector median 18.6x

Interest cover19.4x

Current ratio4.01x

Sales growth 3y+4.6%Sector median +9.6%

Profit growth 3y+5.9%Sector median +13.3%

PEG6.57x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹138 cr vs borrowings ₹3 cr (FY26): cash is higher (net cash).
Operating profit covered interest 19.4x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 5 of the last 5 years (FY26, FY25, FY24, FY23, FY22).
Net loss in 1 of the last 8 quarters.
Revenue was higher than a year earlier in 3 of the last 4 quarters.
Other income was 219% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹48.36 on 2026-10-26: -48.5% from the 52-week high, +4.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹139.20 · low ₹48.36

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	25	26	40	19	26	29	31	24
EBITDA	3	1	0	0	-2	2	4	-4
OPM %	13.3%	2.8%	0.5%	2.2%	-8.5%	5.2%	11.5%	-16.5%
Other income	7	9	2	12	3	1	-0	6
Net profit	8	9	-2	12	0	2	1	1
EPS (₹)	3.66	4.23	-0.95	5.59	0.05	0.90	0.24	0.49
Revenue YoY					+5.3%	+11.1%	-21.3%	+25.2%
Profit YoY					-98.6%	-78.7%	–	-91.7%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	112	92	109	112	106	111
EBITDA	11	8	8	5	3	-1
Net profit	14	13	17	20	15	4
EPS (₹)	6.67	5.90	8.01	9.34	6.71	1.68
Revenue growth		-17.7%	+17.6%	+3.4%	-5.9%	+0.5%
Profit growth		-10.4%	+32.9%	+16.2%	-23.0%	-83.3%
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+4.6%	+1.6%	+0.5%
Net profit	+5.9%	+15.7%	-83.3%
EPS	+4.4%	+14.2%	–
Share price	–	-31.6% (2y)	-41.7%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	135	152	171	186
Borrowings	–	2	5	0	3
Cash & equivalents	–	82	93	113	138
Total assets	–	167	183	223	242
Fixed assets	–	7	11	21	20
Capital work in progress	–	0	0	0	0
Investments	–	6	7	7	7
Receivables	–	47	41	47	41
Inventory	–	13	14	18	13
Payables	–	15	12	19	18

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	2	-5	4	7	10
Cash from investing	-16	1	-13	-1	-12
Cash from financing	6	-3	3	-5	2
Capex	2	1	6	11	4
Free cash flow	-0	-6	-3	-4	6

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	9.4%	11.0%	11.4%	8.1%
ROCE %	–	11.8%	13.4%	15.1%	9.0%
Debtor days	–	185	139	152	141
Inventory days	–	81	73	92	73
Payable days	–	96	63	97	98
Cash conversion cycle (days)	–	170	149	147	116
Working capital days	–	480	446	469	546

Shareholding

Holder	% (2026-09-30)
Promoters	57.19%
FIIs	0.35%
DIIs	0.07%
of which Mutual funds	0.00%
of which Insurance	0.00%
Government	0.00%
Public (non-institutions)	42.39%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	57.29%	57.29%	57.29%	57.29%	57.29%	57.19%	57.19%	57.19%

Promoter group	%
Paresh Chawla	34.26%
Shitul Shah	10.15%
Bakulesh Shah	4.88%
Rima Shah	3.68%
Rupal Shah	2.66%
Soni Chawla	1.55%
Mahendra Singh Chawla	0.00%
Asha Chawla	0.00%
Pravin Shah	0.00%
Bakulesh Shah HUF	0.00%
Pooja Chawla	0.00%
Meeta Sethi	0.00%
Mitin Shah	0.00%
Saraswati Shah	0.00%

17,347 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
ALPA	₹102 cr	28.8x	0.6x	2.5%	3.3%	-1.0%	+4.6%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2024-09-20	Other	Annual General Meeting
2023-09-21	Other	Annual General Meeting
2022-09-20	Other	Annual General Meeting
2021-09-20	Other	Annual General Meeting
2020-09-18	Other	Annual General Meeting
2019-09-19	Other	Annual General Meeting
2018-09-19	Other	Annual General Meeting
2017-09-20	Other	Annual General Meeting
2016-09-21	Other	Annual General Meeting
2015-09-16	Other	Annual General Meeting
2014-09-24	Other	Annual General Meeting
2013-07-31	Other	Annual General Meeting
2012-09-21	Other	Annual General Meeting
2011-09-22	Other	Annual General Meeting
2010-09-02	Other	Annual General Meeting
2009-07-23	Other	Annual General Meeting
2008-09-18	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	ALPA
BSE code	532878
ISIN	INE385I01010
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.